What is LL-37?
LL-37 is the only human member of the cathelicidin family of antimicrobial peptides — a distinction that immediately sets it apart from the hundreds of antimicrobial peptides identified in other species. Its name is both descriptive and specific: “LL” refers to the two leucine residues at its N-terminus, and “37” refers to the total number of amino acids in the mature peptide. That 37-residue sequence is cleaved from a larger precursor protein called hCAP18 (human cationic antimicrobial protein 18, where 18 refers to the protein’s molecular weight in kilodaltons) by the neutrophil serine protease proteinase 3. The cleavage occurs after secretion of hCAP18 from neutrophil secondary granules during degranulation — a process that occurs when neutrophils encounter pathogens and mount an active antimicrobial response.
The cathelicidin family — named after the conserved cathelin domain in the precursor proteins — is present across vertebrate species, with dozens of variants identified in mammals ranging from pigs (PR-39) to rabbits (CAP18) to sheep (SMAP-29). These family members share the common cathelin domain in their precursor structure but diverge substantially in the structure and properties of the mature antimicrobial peptide domain. In humans, evolutionary pressure appears to have converged on a single cathelicidin member, LL-37, suggesting that its specific structure represents a particularly effective solution to the complex demands of human innate immunity — which include not just direct pathogen killing but also modulation of the inflammatory response, promotion of wound healing, and regulation of adaptive immune activation.
LL-37 is found primarily in neutrophil secondary granules but is also expressed in epithelial cells of the respiratory tract, gastrointestinal mucosa, skin, and reproductive tract — positioned at the body’s interfaces with the external environment where pathogen exposure is highest. NK cells, monocytes, and mast cells also produce LL-37 in specific contexts. The peptide’s expression is regulated by vitamin D3, which drives the transcription of the CAMP gene (cathelicidin antimicrobial peptide gene) through vitamin D response elements in its promoter — a connection that has linked vitamin D deficiency to impaired antimicrobial innate immunity and potentially to susceptibility to mycobacterial infections including tuberculosis.
Research interest in LL-37 has expanded considerably beyond its initial characterization as an antimicrobial peptide. Its roles in wound healing, angiogenesis, cancer immunology, and biofilm disruption have made it the subject of multiple ongoing research programs, and synthetic LL-37 is increasingly studied as a potential therapeutic agent for antibiotic-resistant infections, chronic wound management, and cancer immunotherapy enhancement. For a broader overview of antimicrobial and immune-modulating peptides in the research landscape, visit the Peptide Database. The AI Coach can help contextualize LL-37 within the growing field of host defense peptide research.
Research Benefits
- Broad-spectrum antimicrobial activity: LL-37 kills a wide range of gram-positive and gram-negative bacteria, fungi, and enveloped viruses through direct membrane disruption, providing a mechanism of action that is distinct from conventional antibiotics and less prone to resistance development.
- Activity against antibiotic-resistant organisms: LL-37 has demonstrated potent activity against multidrug-resistant bacteria including MRSA, Pseudomonas aeruginosa, and carbapenem-resistant Enterobacteriaceae — organisms for which conventional antibiotic options are severely limited.
- Biofilm disruption: Unlike most conventional antibiotics, LL-37 can penetrate and disrupt bacterial biofilms — the organized, extracellular-matrix-embedded communities of bacteria that are responsible for the majority of chronic infections and for a substantial portion of antibiotic resistance in clinical settings.
- Wound healing acceleration: LL-37 promotes multiple aspects of wound repair including keratinocyte migration, fibroblast activation, neovascularization through VEGF induction, and metalloprotease regulation — making it a multi-modal wound healing promoter rather than simply an antimicrobial agent at the wound site.
- Chemotactic and immune cell recruitment: Through FPRL1 (formyl peptide receptor-like 1, now designated FPR2) binding, LL-37 chemoattracts neutrophils, monocytes, mast cells, and T cells to sites of infection and tissue damage, bridging innate and adaptive immune responses.
- VEGF and IL-8 induction for vascularization: LL-37 directly stimulates production of vascular endothelial growth factor (VEGF) and the angiogenic chemokine IL-8 in epithelial and stromal cells, promoting new blood vessel formation that is essential for wound vascularization and healing in deeper tissue injuries.
- Anti-tumor immune modulation: Emerging research suggests LL-37 can enhance cancer immunosurveillance by stimulating dendritic cell maturation, activating NK cells, and promoting Th1 immune polarization — making it a candidate for investigation as a cancer immunotherapy adjunct.
- Synergy with conventional antibiotics: LL-37 has been shown to potentiate the activity of several conventional antibiotics against resistant organisms, including through membrane permeabilization that improves antibiotic intracellular penetration — suggesting combination applications in multidrug-resistant infection management.
- Anti-inflammatory immune modulation: Beyond direct antimicrobial killing, LL-37 modulates the inflammatory response — suppressing LPS-induced TLR4 signaling, reducing excessive cytokine production, and helping transition the inflammatory response from acute to resolution — reducing the secondary tissue damage caused by overzealous immune activation.
How LL-37 Works
Amphipathic Alpha-Helix Membrane Disruption
The fundamental mechanism by which LL-37 kills bacteria is physical disruption of the bacterial cell membrane, mediated by the peptide’s amphipathic alpha-helical structure. “Amphipathic” means that the helix has a distinctly hydrophobic face on one side and a positively charged (cationic) face on the other — an arrangement that is critical for both membrane targeting and disruption. The cationic face (positively charged lysine and arginine residues) is electrostatically attracted to the negatively charged phospholipid head groups that dominate bacterial membranes — particularly the phosphatidylglycerol and cardiolipin that are abundant in gram-positive and gram-negative bacterial membranes. Mammalian cell membranes are predominantly zwitterionic (phosphatidylcholine, sphingomyelin) rather than anionic, which provides the electrostatic selectivity that allows LL-37 to preferentially target bacterial membranes over host cell membranes.
Once LL-37 is electrostatically tethered to the bacterial membrane surface, the hydrophobic face of the helix inserts into the hydrophobic core of the lipid bilayer. Multiple LL-37 molecules accumulate at the membrane, and above a critical local concentration, they disrupt membrane integrity through one of several proposed models: the carpet model (covering the membrane surface until it disintegrates like a detergent), the barrel-stave model (inserting parallel to each other to form a membrane-spanning pore), or the toroidal pore model (forming curved pores lined by both peptide and lipid headgroups). Regardless of the precise structural model, the functional outcome is loss of membrane integrity — ions and small molecules leak out, the electrochemical gradient is dissipated, ATP synthesis and active transport fail, and the bacterium dies. This mode of action is mechanistically distinct from all classical antibiotic classes (beta-lactams, aminoglycosides, fluoroquinolones, etc.), which means that bacteria with resistance mechanisms to those classes are generally still susceptible to LL-37’s membrane disruption — a property that makes LL-37 and its analogs genuinely valuable tools in the fight against multidrug-resistant infections.
FPRL1 Chemoattraction and Immune Cell Recruitment
Beyond its direct bactericidal activity, LL-37 functions as a potent immunomodulatory signaling molecule that actively recruits and activates immune cells at sites of infection and tissue injury. A key receptor through which LL-37 mediates these effects is FPR2 (formyl peptide receptor 2, historically called FPRL1 for formyl peptide receptor-like 1). FPR2 is a G protein-coupled receptor expressed on neutrophils, monocytes, macrophages, mast cells, dendritic cells, and T lymphocytes — essentially the major cellular components of the innate immune response.
When LL-37 binds FPR2 on neutrophils, it triggers chemotactic migration toward the LL-37 source — moving neutrophils down a concentration gradient toward the infection or injury site. The same receptor engagement also primes neutrophils for enhanced bactericidal activity: increased respiratory burst, enhanced phagocytosis, and upregulated degranulation. On mast cells, FPR2-mediated LL-37 signaling triggers selective degranulation and chemokine secretion that recruits additional immune cells — particularly T cells and NK cells — creating an amplifying signal that escalates the innate immune response. Monocyte-derived dendritic cells exposed to LL-37 through FPR2 signaling undergo accelerated maturation and enhanced antigen presentation, connecting the innate response to adaptive immune activation. This multi-cellular immunomodulatory cascade means that LL-37 at infection sites does far more than directly kill bacteria — it orchestrates a coordinated recruitment and activation of the cellular immune response that dramatically amplifies the host’s ability to clear infection.
The FPR2 receptor is also activated by other endogenous and pathogen-derived signals including lipoxin A4 (LXA4, which has anti-inflammatory and resolution-promoting effects), providing an interesting convergence point where LL-37 may modulate not just inflammation initiation but also its resolution depending on context and concentration. This dual inflammatory/resolution potential through the same receptor adds complexity to LL-37’s immune modulatory profile that is still being actively characterized.
VEGF and IL-8 Induction for Wound Vascularization
One of LL-37’s most therapeutically important properties for wound healing and tissue repair is its ability to directly induce vascular endothelial growth factor (VEGF) and the CXC chemokine IL-8 (CXCL8) from epithelial cells, keratinocytes, and stromal fibroblasts at wound sites. This places LL-37 at the center of the angiogenic response that is essential for healing anything other than a superficial skin abrasion.
VEGF is the master regulator of angiogenesis — new blood vessel formation. In wound healing, adequate vascularization is critical for delivering oxygen, nutrients, and additional immune cells to the healing tissue and for removing metabolic waste products. Wounds that lack adequate VEGF-driven angiogenesis develop chronic hypoxic conditions that prevent tissue granulation and re-epithelialization, leading to the chronic, non-healing wound phenotype that affects millions of diabetic, venous insufficiency, and pressure ulcer patients. LL-37’s ability to directly induce VEGF expression in surrounding cells means it contributes to the angiogenic phase of wound healing independent of its antimicrobial activity — addressing two distinct components of the wound healing challenge simultaneously.
IL-8 (CXCL8) is an angiogenic chemokine that stimulates endothelial cell migration and proliferation in addition to its classical role as a neutrophil chemoattractant. In the wound healing context, IL-8-driven endothelial migration contributes to the sprouting of new capillaries into the granulation tissue forming in the wound bed. LL-37-induced IL-8 production thus supports angiogenesis through a second pathway parallel to VEGF. The dual induction of both major angiogenic signals — VEGF for vessel growth and IL-8 for endothelial chemotaxis — makes LL-37’s pro-angiogenic activity particularly robust and relevant to healing in tissues where poor vascularization is a primary barrier to recovery.
Research Findings
Activity Against Antibiotic-Resistant Pathogens
The antibiotic resistance crisis has given LL-37 and related host defense peptides renewed clinical relevance. With gram-negative bacteria like Pseudomonas aeruginosa and Klebsiella pneumoniae developing resistance to carbapenems (the “last resort” antibiotics for many gram-negative infections), and gram-positive organisms like MRSA accumulating resistance to multiple antibiotic classes, the therapeutic pipeline for difficult infections is becoming dangerously thin. LL-37’s mechanism of membrane disruption is generally not affected by the major resistance mechanisms that undermine conventional antibiotics — because it doesn’t target a specific enzyme or biosynthetic pathway that bacteria can mutate to resist, but rather attacks the fundamental structural integrity of the bacterial membrane.
Multiple in vitro studies have demonstrated LL-37 activity against clinical MRSA isolates, Pseudomonas aeruginosa strains (including mucoid strains from cystic fibrosis lungs), and Acinetobacter baumannii. Minimum inhibitory concentrations (MICs) for LL-37 against these organisms are typically in the range of 1–10 μg/mL in vitro — potent antimicrobial activity. Importantly, bacteria appear to develop resistance to LL-37 much more slowly than to conventional antibiotics, likely because developing resistance to membrane disruption would require wholesale remodeling of bacterial membrane lipid composition — a metabolically costly and evolutionarily constrained change. This resistance-barrier advantage is one of the most compelling arguments for developing LL-37 and its analogs as therapeutic antimicrobials.
In vivo animal models of infection (including lung, wound, and sepsis models) have shown that exogenous LL-37 administration reduces bacterial burden and improves survival outcomes in animals challenged with lethal doses of bacteria, providing proof-of-concept for therapeutic application beyond in vitro potency data.
Biofilm Disruption: Tackling Chronic Infections
Biofilms are organized bacterial communities enclosed in an extracellular polysaccharide matrix that provides remarkable protection against antibiotics, immune cells, and environmental stressors. It is estimated that biofilm-associated infections account for over 80% of all chronic infections in the developed world — from diabetic foot ulcers and pressure sores to catheter-associated urinary tract infections, implant-associated infections, and chronic sinusitis. The hallmark of biofilm infections is their extraordinary recalcitrance: bacteria within biofilms may require 100–1,000 times higher antibiotic concentrations to achieve killing compared to the same bacteria in planktonic (free-floating) form, explaining why repeated antibiotic courses often fail to eradicate biofilm-associated chronic infections.
LL-37 has been shown to inhibit biofilm formation and disrupt pre-formed biofilms at concentrations that are significantly lower than those required to kill planktonic bacteria. The mechanisms by which LL-37 disrupts biofilms include: direct destabilization of the extracellular polysaccharide matrix (through electrostatic interactions with the anionic biofilm matrix components), inhibition of the quorum-sensing signals that coordinate biofilm formation and maintenance, disruption of the bacterial membrane integrity of cells within the biofilm, and physical dispersal of cells from the biofilm surface that renders them vulnerable to immune clearance. This biofilm-disrupting activity may be one of the most practically important antimicrobial properties of LL-37 from a clinical standpoint, representing a mechanism of action where no currently approved antibiotics have comparable effectiveness.
Wound Healing Studies and Chronic Wound Applications
Wound healing represents one of the most extensively studied and clinically compelling applications for LL-37. Research has established LL-37’s role in multiple phases of wound repair: it contributes to the early inflammatory phase through its antimicrobial and chemotactic activities, to the proliferative phase through its effects on keratinocyte migration and fibroblast activation, and to the angiogenic phase through VEGF and IL-8 induction. This multi-phase involvement makes LL-37 a genuinely pleiotropic wound healing agent rather than a compound that addresses only one aspect of repair.
Particularly interesting from a clinical perspective is the observation that LL-37 levels are markedly deficient in chronic non-healing wounds — including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Studies measuring LL-37 in wound fluid from chronic wounds versus acute wounds show dramatically lower concentrations in the chronic wound environment, consistent with the hypothesis that LL-37 deficiency is a contributor to (rather than merely a result of) the non-healing phenotype. This suggests that topical or local delivery of LL-37 or LL-37 analogs to chronic wounds might address a genuine biological deficit in wound healing capacity. Multiple research groups have explored LL-37 delivery to wounds using hydrogel, liposomal, and nanoparticle carrier systems, with encouraging results in preclinical models showing accelerated wound closure, improved re-epithelialization, and reduced bacterial burden compared to untreated controls.
Cancer Immunotherapy Potential
The relationship between LL-37 and cancer is genuinely complex, and it is important to understand that complexity rather than oversimplifying it. Early research identified LL-37 as having direct cytotoxic activity against certain cancer cell lines at high concentrations — an effect mediated through membrane disruption similar to its antimicrobial mechanism. However, LL-37’s cancer-relevant biology goes well beyond direct tumor cell killing, and the emerging picture from more recent research is that its primary value in oncology may be through immune modulation rather than direct cytotoxicity.
LL-37 has been shown to stimulate dendritic cell differentiation and maturation, enhance NK cell cytotoxicity, promote Th1 immune polarization (the type of cellular immune response most effective against cancer), and activate TLR9 signaling when complexed with DNA — a pathway that drives innate immune activation against tumors. In animal cancer models, local or systemic LL-37 administration has been shown to reduce tumor growth and enhance responses to checkpoint inhibitor immunotherapy, suggesting that LL-37 may serve as a useful immunotherapy adjunct by improving the immunological tone of the tumor microenvironment. The complex immunomodulatory effects of LL-37 in cancer are an active research area, with the understanding that dose, timing, tumor type, and the specific immune context all influence whether LL-37’s net effect is pro-tumor or anti-tumor in any given setting — adding important nuance that should be considered before extrapolating from any single study.
Innate Immunity Regulation and Vitamin D Connection
One of the most clinically practical findings connecting LL-37 biology to everyday immunology is the link between vitamin D3 status and LL-37 expression. The CAMP gene (encoding hCAP18/LL-37) contains a vitamin D response element (VDRE) in its promoter region that is directly activated by the vitamin D receptor (VDR) upon binding the active vitamin D3 metabolite 1,25-dihydroxyvitamin D3. This means that adequate vitamin D3 status is required for optimal LL-37 production in macrophages, monocytes, neutrophils, and epithelial cells. Vitamin D deficiency — which is extraordinarily prevalent in Northern latitudes during winter months and in populations with limited sun exposure — directly impairs LL-37 production and therefore weakens a key arm of innate antimicrobial defense.
This mechanism provides a plausible biological basis for several well-established epidemiological associations: the winter seasonality of respiratory infections, the higher infection susceptibility of vitamin D-deficient populations, and the protective associations observed between higher vitamin D status and lower tuberculosis risk. The connection is not merely theoretical — intervention studies have shown that vitamin D3 supplementation raises LL-37 levels in deficient individuals, and in vitro studies of macrophages from vitamin D-deficient donors show improved mycobacterial killing after vitamin D3 treatment through an LL-37-dependent mechanism. This VDR-CAMP axis represents one of the most mechanistically well-characterized pathways linking a nutritional factor to an innate immune effector function.
Dosage and Administration
Research Doses and Delivery Systems
LL-37 has been studied across a range of doses and delivery platforms in preclinical research. In vitro studies establish antimicrobial activity at concentrations typically between 1 and 16 μg/mL depending on the bacterial species, biofilm status, and assay conditions. In animal wound healing and infection models, doses are typically in the range of 1–10 μg per wound site for topical applications, or 1–5 mg/kg for systemic administration. The critical challenge for LL-37 as a therapeutic is not potency — the compound is highly active — but delivery: LL-37 is susceptible to protease degradation in wound fluid and in biological fluids, meaning that direct application of unformulated LL-37 may not maintain therapeutic concentrations at target sites for adequate duration. Advanced delivery systems being investigated include hydrogel matrices that release LL-37 gradually, liposomal encapsulation that protects the peptide from proteolytic degradation, and nanoparticle-based delivery platforms. These formulation approaches are still largely in the research phase, and no LL-37 formulation has yet received regulatory approval for any clinical indication. The Peptide Calculator can assist with concentration and dilution calculations for research applications.
Route of Administration
The route of LL-37 administration depends entirely on the intended application. For wound healing and topical antimicrobial applications, direct topical application to wound surfaces is the target delivery route, with formulations designed to provide sustained peptide release at the wound site. For systemic antimicrobial applications, intravenous or subcutaneous injection would be required, but the systemic use of LL-37 faces the challenge that the peptide is cytotoxic to mammalian cells at higher concentrations — the membrane disruption mechanism that kills bacteria can also damage red blood cells (hemolysis) and other mammalian cells when concentrations are too high. This hemolytic concern limits the achievable systemic dose and has driven research toward modified analogs of LL-37 with improved selectivity between bacterial and mammalian membranes. Inhaled delivery for lung infections (particularly relevant for Pseudomonas aeruginosa in cystic fibrosis) is another route under active investigation, exploiting the direct access of inhaled agents to the airway surface liquid where LL-37 normally functions.
Analog Development and Stability Enhancement
Because native LL-37 has stability limitations that constrain its therapeutic development, significant research effort has gone into developing modified analogs with improved properties. Key research directions include: truncated fragments of LL-37 that retain antimicrobial activity with reduced hemolytic toxicity (17BIPHE2, LL-37 fragments 1–12, etc.), D-amino acid substitution analogs for protease resistance (analogous to the DRI strategy used for FOXO4-DRI), and peptidomimetics that retain the amphipathic helix pharmacophore while using non-amino acid building blocks for improved stability. GF-17, a truncated 17-residue fragment of LL-37 spanning amino acids 17–32, has been studied as a candidate with antimicrobial potency approaching that of full-length LL-37 but with reduced cytotoxicity and improved selectivity. These analog development programs represent the primary path toward clinical translation of the LL-37 concept. The Peptide Database tracks related host defense peptide research developments.
Current Research Status and Clinical Pipeline
As of early 2026, LL-37 has not received regulatory approval for any clinical indication. It is the subject of active preclinical and some early-phase clinical investigation in wound healing, antibiotic-resistant infection, and oncology applications. Clinical trials of formulated LL-37 for venous leg ulcers and other chronic wound indications have been conducted, with phase 1 and 2 data showing tolerability and preliminary efficacy signals. The wound healing application is generally considered the most clinically near-term because topical delivery avoids the systemic hemolytic concerns that complicate systemic use, and the biological deficit of LL-37 in chronic wounds provides a compelling therapeutic rationale. Follow developments in this area through the AI Coach, which can summarize current clinical trial status and emerging publications.
Safety and Side Effects
Hemolytic Activity and Therapeutic Window
The primary safety concern for LL-37 as a therapeutic is hemolytic activity — the ability to disrupt red blood cell membranes in the same way it disrupts bacterial membranes. At concentrations above approximately 20–40 μg/mL, LL-37 produces measurable hemolysis in vitro. The therapeutic window — the range between concentrations sufficient to kill bacteria and concentrations producing significant hemolysis — narrows at higher doses. This concern is substantially more relevant for systemic (IV or SC) administration than for topical applications, where the peptide does not reach systemic circulation at concentrations that would affect red blood cells. The hemolytic issue has been a major driver of the analog development programs described above, as improved selectivity for bacterial over mammalian membranes would dramatically expand the therapeutic utility of LL-37-based agents for systemic infection applications.
Immunological Effects and Inflammatory Modulation
LL-37’s potent immunomodulatory activity is intrinsically dual-edged: the same properties that make it effective at recruiting and activating immune cells during infection can potentially contribute to excessive or misdirected inflammation in certain pathological contexts. LL-37 is elevated in a number of autoimmune and inflammatory conditions — particularly psoriasis, systemic lupus erythematosus (SLE), and rosacea. In psoriasis, LL-37 released from damaged keratinocytes complexes with self-DNA released from necrotic cells and activates TLR9-driven plasmacytoid dendritic cell activation, triggering the interferon-alpha response that drives psoriatic inflammation. This means that conditions characterized by excessive LL-37 production or activity represent potential contraindications for exogenous LL-37 supplementation — and that the appropriate clinical application of LL-37 requires careful consideration of the patient’s underlying immune status. In the context of infection or wound healing in immunologically normal individuals, LL-37’s immunostimulatory properties are beneficial; in individuals with autoimmune disease or abnormal immune activation, they require more careful evaluation.
Concentration-Dependent Cytotoxicity
Consistent with its membrane-disruption mechanism of action, LL-37 shows concentration-dependent cytotoxicity against mammalian cells at higher concentrations. In vitro, at concentrations above roughly 10–20 μg/mL, LL-37 begins to affect mammalian cell viability — damaging cell membranes in a manner analogous to its antibacterial activity. At physiological concentrations in biological fluids (typically well below 1 μg/mL), LL-37 is not toxic to host cells, and its selectivity for bacterial membranes at these concentrations is maintained by the electrostatic differences described in the mechanism section. Therapeutic use — particularly topical or inhaled delivery — must be designed to maintain concentrations in the antimicrobially effective but non-cytotoxic range at target sites. Advanced delivery formulations that provide controlled-release at appropriate concentrations are therefore not just a convenience but a genuine safety requirement for effective therapeutic development.
Frequently Asked Questions
LL-37 is both — it is a peptide that functions as an antimicrobial agent, among its many biological roles. It belongs to the category of “host defense peptides” or “antimicrobial peptides” (AMPs), which are short peptides produced by organisms as part of their innate immune arsenal. What distinguishes LL-37 from most synthetic antimicrobial peptides is that it is the naturally occurring human molecule, with all the evolutionary optimization that implies — it kills pathogens, modulates immune responses, promotes wound healing, and regulates inflammation as part of a coherent physiological system rather than as a narrowly designed antimicrobial drug.
Most other mammalian species have evolved multiple cathelicidin family members — mice have four (CRAMP and others), pigs have several, and cows have over a dozen. The single human cathelicidin appears to reflect evolutionary selection for a versatile, multi-functional host defense molecule rather than a family of more specialized peptides. LL-37’s combination of broad-spectrum antimicrobial activity, immunomodulatory functions, and wound healing properties may represent an optimized solution that eliminated selection pressure for additional family members. Alternatively, other cathelicidin genes may have been lost from the human genome over evolutionary time — the single surviving member clearly provides a multifunctional benefit that maintained strong positive selection.
Defensins are another major family of human antimicrobial peptides, including the alpha-defensins (HNP1-4 in neutrophils, HD5-6 in intestinal Paneth cells) and beta-defensins (hBD1-4 in epithelial cells). Like LL-37, defensins are cationic peptides that kill bacteria through membrane disruption. However, they differ structurally (defensins have a characteristic three-disulfide-bonded beta-sheet structure rather than LL-37’s alpha-helix), in their tissue distribution, and in their specific immunomodulatory functions. LL-37 and defensins are often co-expressed and co-secreted during infection, where they appear to act synergistically — together covering a broader spectrum of antimicrobial activity than either family achieves alone. The two systems can also regulate each other’s expression through complex inflammatory signaling networks.
In vitro and animal studies have demonstrated clear activity of LL-37 against MRSA, including clinical MRSA isolates. However, “can be used” in the clinical sense requires distinguishing between the preclinical proof-of-concept (yes, LL-37 kills MRSA in laboratory conditions) and approved clinical therapy (no, LL-37 has not been approved for MRSA treatment). The translation from in vitro activity to approved clinical use requires resolving delivery challenges (achieving therapeutic concentrations at infection sites without systemic toxicity), demonstrating safety in humans, and conducting controlled clinical trials that establish efficacy versus standard of care. These steps are in progress for various LL-37 analogs and formulations, but no LL-37-based product is currently approved for MRSA treatment.
hCAP18 (human cationic antimicrobial protein 18) is the full-length precursor protein from which LL-37 is cleaved. The protein consists of a conserved N-terminal signal peptide, the cathelin domain (which gives the cathelicidin family its name), and the C-terminal 37-amino acid antimicrobial domain that becomes LL-37 upon cleavage. hCAP18 is stored in inactive form in neutrophil secondary granules and is secreted during neutrophil degranulation. Activation requires cleavage by the serine protease proteinase 3, which removes the cathelin domain and releases the active LL-37 peptide. The precursor form (hCAP18) may have distinct biological activities from mature LL-37, and there is evidence that the cathelin domain itself can modulate inflammatory responses — adding another layer of biological complexity to cathelicidin biology beyond the well-characterized LL-37 mature peptide.
Multiple factors contribute to LL-37 deficiency in chronic wounds. Proteolytic enzymes — particularly matrix metalloproteinases and serine proteases — are dramatically elevated in chronic wound fluid and rapidly degrade LL-37 before it can exert its effects. Vitamin D deficiency, which impairs CAMP gene transcription, is highly prevalent in patients with chronic wounds (particularly the elderly, diabetic, and nursing home-resident populations most affected by chronic wounds). Biofilm formation itself consumes LL-37 through the electrostatic sequestration by the negatively charged biofilm matrix, reducing the effective concentration available for antimicrobial activity. The hypoxic, low-pH environment of chronic wounds may also reduce LL-37 production and activity. Addressing these compounding deficits — through vitamin D optimization, protease inhibition, biofilm disruption, and direct LL-37 supplementation — represents a multi-pronged approach to restoring effective innate antimicrobial defense in the chronic wound environment.
This hypothesis received considerable attention early in the COVID-19 pandemic. The logic is: vitamin D3 drives LL-37 expression → LL-37 has antiviral activity (documented against enveloped viruses) → vitamin D deficiency reduces LL-37 → reduced innate antiviral defense → potentially increased COVID-19 susceptibility or severity. The epidemiological associations between vitamin D deficiency and COVID-19 outcomes were suggestive but confounded by multiple variables. LL-37’s direct antiviral mechanism (membrane disruption of enveloped viruses) is biologically plausible. However, the clinical evidence for vitamin D supplementation improving COVID-19 outcomes has been mixed in controlled trials, and LL-37-specific antiviral effects in COVID-19 have not been definitively characterized. The hypothesis remains scientifically interesting and mechanistically plausible but not yet definitively proven in the COVID-19 context.
The Peptide Database contains entries on thymosin beta-4 (TB-500), BPC-157, and other peptides with wound healing and immune modulation research. The AI Coach can provide detailed comparisons between different immune-active peptides and help contextualize the growing field of host defense peptide therapeutics. For peptide handling, reconstitution, and dosing calculations applicable to LL-37 research applications, the Peptide Calculator provides the essential practical tools.
References
- Zanetti M. “Cathelicidins, multifunctional peptides of the innate immunity.” Journal of Leukocyte Biology. 2004;75(1):39–48. PubMed
- Steinstraesser L, et al. “Innate defense regulator peptides and the antimicrobial peptide LL-37 are agonists of TLR3 in keratinocytes.” Wound Repair and Regeneration. 2010;18(4):373–380. PubMed
- Lau YE, et al. “Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells.” Infection and Immunity. 2005;73(1):583–591. PubMed
- Nijnik A, Hancock R. “Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections.” Emerging Health Threats Journal. 2009;2:e1. PubMed
- Ong PY, et al. “Endogenous antimicrobial peptides and skin infections in atopic dermatitis.” New England Journal of Medicine. 2002;347(15):1151–1160. PubMed
- Koczulla R, et al. “An angiogenic role for the human peptide antibiotic LL-37/hCAP-18.” Journal of Clinical Investigation. 2003;111(11):1665–1672. PubMed
- Schauber J, Gallo RL. “Antimicrobial peptides and the skin immune defense system.” Journal of Allergy and Clinical Immunology. 2008;122(2):261–266. PubMed
- Heilborn JD, et al. “The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.” Journal of Investigative Dermatology. 2003;120(3):379–389. PubMed
- Hancock RE, Sahl HG. “Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies.” Nature Biotechnology. 2006;24(12):1551–1557. PubMed
- Wang G, et al. “Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles.” Journal of Biological Chemistry. 2008;283(47):32637–32643. PubMed